USFDA Issues Warning Letter to Telangana's Aurobindo Pharma Unit, Shares Fall 2%
Summarized by AI; it may make mistakes. Check important info
Summarized by AI; it may make mistakes. Check important info
Shares in Aurobindo Pharma slipped by up to 2% on Friday following news that the US Food and Drug Administration (USFDA) has issued a warning letter to a formulation manufacturing plant in Telangana, operated by its subsidiary Eugia Pharma Specialities Ltd.
The regulatory action targets Unit-I, which was subjected to an inspection by the USFDA between February 16 and February 27 earlier this year. Following the audit, the regulator issued four observations and initially designated the facility under 'Official Action Indicated' (OAI) status.
Supply Lines Unaffected Despite Revenue Exposure
Addressing market concerns, the drugmaker confirmed that the regulatory notice will not disrupt current product supplies to the US market. Aurobindo Pharma also noted that Unit-I accounts for roughly 2% of the group's overall revenue, limiting the immediate commercial risk.
The news follows the company's Q1 FY27 financial results, where net profit reached ₹1,032 crore alongside revenue from operations of ₹9,150 crore. Aurobindo stated that it is actively collaborating with the USFDA to reinforce its quality and compliance systems.
Regulatory Escalation and Stock Response
The escalation to a warning letter follows a Form 483 issued in March, which initially listed nine inspection observations before the USFDA determined the OAI status. Under USFDA procedures, an OAI classification indicates that identified regulatory violations require formal administrative or corrective action.
Following the disclosure, Aurobindo Pharma shares fell over 2% to an intraday low of ₹1,621.30 on the Bombay Stock Exchange (BSE). The stock has traded between a 52-week high of ₹1,682 and a 52-week low of ₹1,017.
While the warning letter highlights regulatory friction at the Telangana facility, the limited 2% revenue contribution and undisturbed supply chain mitigate immediate operational damage. Re-establishing full compliance at Unit-I will nonetheless remain vital for safeguarding investor confidence in the company's US growth pipeline.
